<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605904</url>
  </required_header>
  <id_info>
    <org_study_id>080058</org_study_id>
    <secondary_id>08-AA-0058</secondary_id>
    <nct_id>NCT00605904</nct_id>
  </id_info>
  <brief_title>Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics</brief_title>
  <official_title>Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if acamprosate, a drug approved to treat alcoholism, decreases
      alcohol cravings in alcohol-dependent subjects following infusions of yohimbine and mCPP.
      Yohimbine causes anxiety and may provoke a desire for alcohol; mCPP induces a feeling of
      having had a few drinks, which often creates a desire for more drinks. If acamprosate can
      prevent a craving following these stimuli, then the effectiveness of new experimental drugs
      for treating alcoholism can be tested for their ability to block yohimbine or mCPP-induced
      cravings. This type of investigation would be less expensive and less time-consuming than
      conducting clinical trials with alcohol-dependent people.

      People between 21 and 65 years of age who are alcohol-dependent and have been drinking
      regularly for at least 1 month before entering the study may be eligible to participate.

      Participants are admitted to the NIH Clinical Center for about 35 days, during which time
      they are asked to participate in an alcohol treatment program. They may request passes to
      leave the hospital during the day but must return overnight. Upon return to the hospital,
      subjects are required to take a breathalyzer test for alcohol and urine screen for drug use.
      Participants found to have used drugs or consumed alcohol while away from the hospital are
      terminated from the study.

      Participants are randomly assigned to take acamprosate or placebo pills three times a day for
      about 2 weeks. They are then given three intravenous (through a vein) infusions, 5 to 7 days
      apart, each containing either yohimbine, mCPP or placebo. The drugs are infused for 20
      minutes following a 1-hour infusion of saline (salt water). Subjects complete two
      questionnaires - an alcohol urge questionnaire to assess the desire for alcohol and a PASS
      rating scale to assess anxiety - several times during the study and during the infusions....
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The objective of the present study is to establish, in our laboratory, a published
      model of pharmacologically induced alcohol craving, and carry out an initial evaluation of
      its predictive validity for efficacy in treatment of alcoholism. Two pharmacological
      challenges are tested: 1. The alpha2-adrenergic antagonist yohimbine, which reliably induces
      reinstatement of alcohol seeking in experimental animals, but has produced less clear results
      in humans. 2. The serotonergic compound mCPP, which has been reported to robustly increase
      alcohol craving in human alcoholics, but for which animal data are less clear. Our objective
      study is to evaluate craving responses to infusion of yohimbine or mCPP using optimal
      assessment tools and subject population, and establish their sensitivity to the clinically
      effective alcoholism medication acamprosate.

      Study Population: The study will be carried out in 60 subjects aged 21-65 years, with alcohol
      dependence as their primary complaint, and without other serious medical or psychiatric
      conditions. An additional inclusion criterion will be elevated trait anxiety as measured by
      the Spielberger Trait Anxiety Inventory. Subjects will be admitted to the NIAAA research
      inpatient unit at the NIH Clinical Research Center (CRC) through the platform training and
      natural history protocol (05-AA-0121 Assessment and Treatment of People with Alcohol Drinking
      Problems ), which provides basic assessments and standard withdrawal treatment if needed.
      Patients will enter into the present protocol once such treatment, if needed, is completed.

      Design: Following inclusion, subjects will be randomized to acamprosate (n=25) or placebo
      (n=25), receiving either 3 tablets of 333mg acamprosate three times daily, or receiving
      identically looking placebo. Following a minimum of 2 weeks of treatment, subjects will
      undergo three challenge sessions, a minimum of 5 days apart, with yohimbine, m-CPP or placebo
      infusion, in counterbalanced order.

      Outcome Measures: During the challenge sessions, subjective cravings for alcohol will be
      assessed using the Alcohol Urge Questionnaire. Neuroendocrine and cardiovascular measures
      will be collected for exploratory purposes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Craving Rating in Response to Saline Infusion</measure>
    <time_frame>180 minutes after the start of the infusion</time_frame>
    <description>Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol Craving Rating in Response to Meta-Chlorophenylpiperazine</measure>
    <time_frame>180 minutes after the start of the infusion</time_frame>
    <description>Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol Craving Rating in Response to Yohimbine Infusion</measure>
    <time_frame>180 minutes after the start of the infusion</time_frame>
    <description>Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Acamprosate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 tablets of 333mg acamprosate orally, three times daily (total dose of 999 mg) for a minimum of 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received 3 tablets of placebo orally, three times daily, for a minimum of 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acamprosate</intervention_name>
    <description>orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)</description>
    <arm_group_label>Acamprosate</arm_group_label>
    <other_name>Campral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yohimbine</intervention_name>
    <description>Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes</description>
    <arm_group_label>Acamprosate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Yohimbe</other_name>
    <other_name>Yocon</other_name>
    <other_name>Yohimex</other_name>
    <other_name>Aphrodyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mCPP</intervention_name>
    <description>Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg</description>
    <arm_group_label>Acamprosate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>3-CPP</other_name>
    <other_name>CPP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the &quot;Saline Infusion&quot; milestone, and one time immediately following the &quot;Yohimbine Infusion&quot; milestone)</description>
    <arm_group_label>Acamprosate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline Flush</other_name>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Subjects will be 60 recently detoxified alcoholics according to the following criteria:

          -  DSM-IV diagnosis of alcohol dependence on SCID, alcohol problems as primary complaint
             among substance use disorder, and alcohol use within the last month.

          -  Spielberger trait anxiety (21) score greater than 39

          -  Age 21-65

          -  Females of childbearing potential must agree to use a reliable method of birth control
             during the study. Reliable methods of birth control include oral contraceptives or
             Norplant(Registered Trademark); barrier methods such as diaphragms with contraceptive
             jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, or
             intrauterine devices; a partner with a vasectomy; or abstinence from intercourse.

        EXCLUSION CRITERIA:

          -  People who present with significant medical problems which in the assessment of the
             Lead Associate Investigator contraindicate administration of any of the study drugs.
             Examples are patients requiring intensive medical or diagnostic management, such as
             uncontrolled hypertension, serious GI bleeding, major organ or body system dysfunction
             such as decompensated liver disease, renal failure, myocardial ischemia, congestive
             heart failure or cerebrovascular disease, major endocrine problems such as
             uncontrolled diabetes, pancreatic or thyroid disease, or glaucoma.

          -  People who are infected with the Human Immunodeficiency Virus (HIV).

          -  People with the following specific neuro-psychiatric disorders: any psychotic disorder
             including schizophrenia; bipolar affective disorder; or panic disorder.

          -  People with any other condition that impairs judgment or cognitive function to an
             extent that precludes them from providing informed consent or complying with treatment
             (incompetent individuals); or that requires management with pharmacotherapy that would
             make the subject ineligible for participation.

          -  Contraindications for acamprosate (previously exhibited hypersensitivity to
             acamprosate calcium or any of its components; or severe renal impairment, manifested
             as creatinine clearance of 30 mL/min or less.

          -  Contraindications for yohimbine or mCPP, such as liver or renal disease; chronic
             inflammation of the sexual organs or prostate gland; history of gastric and duodenal
             ulcers; glaucoma; hypersensitivity to yohimbine or mCPP

          -  People who are unlikely or unable to complete the treatment program because they
             become, or are likely to be, incarcerated while on the protocol.

          -  People who are required to receive treatment by a court of law or who are
             involuntarily committed to treatment.

          -  Pregnancy or lactation (negative pregnancy test required)

          -  Regular use of psychotropic medication, physician prescribed or purchased over the
             counter (e.g. antidepressant, lithium, antipsychotic, anxiolytic, antiepileptic, nasal
             decongestants in tablet form) or blood pressure medication (e.g. beta-blockers,
             calcium antagonists, ACE-inhibitors or AT1 antagonists) within the last 4 weeks, with
             the exception of benzodiazepines administered within the NIAAA program as part of
             alcohol withdrawal treatment. Specifically, no subject will be taken off psychoactive
             medications for the purpose of enrollment in this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76. Epub 2006 Mar 20. Review.</citation>
    <PMID>16545872</PMID>
  </reference>
  <reference>
    <citation>Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 2007 Aug;30(8):399-406. Epub 2007 Jul 16. Review.</citation>
    <PMID>17629579</PMID>
  </reference>
  <reference>
    <citation>Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995 Jun;19(3):600-6.</citation>
    <PMID>7573780</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <results_first_submitted>September 21, 2011</results_first_submitted>
  <results_first_submitted_qc>May 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2012</results_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Markus Heilig</investigator_full_name>
    <investigator_title>Clinical Director, NIAAA</investigator_title>
  </responsible_party>
  <keyword>Chemical Stressor</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Yohimbine</keyword>
  <keyword>Acamprosate</keyword>
  <keyword>Craving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acamprosate</mesh_term>
    <mesh_term>Yohimbine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acamprosate</title>
          <description>Subjects received 3 tablets of 333mg acamprosate three times daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects received 3 tablets of placebo three times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Data Collection and Dosing</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">While 37 subjects were enrolled in the protocol, only 34 were randomized to a study arm</participants>
                <participants group_id="P2" count="21">While 37 subjects were enrolled in the protocol, only 34 were randomized to a study arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Infusion Sessions</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Saline Infusion</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>mCPP Infusion</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Yohimbine Infusion</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15">Milestones (infusions) were not received in the same order for each subjects so are not consecutive.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">Subjects who completed all three types of infusion (given in a different order for each subject)</participants>
                <participants group_id="P2" count="13">Subjects who completed all three types of infusion (given in a different order for each subject)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acamprosate</title>
          <description>Subjects received 3 tablets of 333mg acamprosate three times daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects received 3 tablets of placebo three times daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Craving Rating in Response to Saline Infusion</title>
        <description>Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving.</description>
        <time_frame>180 minutes after the start of the infusion</time_frame>
        <population>The analyses included only those subjects who completed all three types of infusions (saline, meta-Chlorophenylpiperazine, and yohimbine)</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Subjects received 3 tablets of 333mg acamprosate three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received 3 tablets of placebo three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Craving Rating in Response to Saline Infusion</title>
          <description>Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving.</description>
          <population>The analyses included only those subjects who completed all three types of infusions (saline, meta-Chlorophenylpiperazine, and yohimbine)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.704" spread="0.715"/>
                    <measurement group_id="O2" value="1.766" spread="0.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Craving Rating in Response to Meta-Chlorophenylpiperazine</title>
        <description>Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving.</description>
        <time_frame>180 minutes after the start of the infusion</time_frame>
        <population>The analyses included only those subjects who completed all three types of infusions (saline, meta-Chlorophenylpiperazine, and yohimbine)</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Subjects received 3 tablets of 333mg acamprosate three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received 3 tablets of placebo three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Craving Rating in Response to Meta-Chlorophenylpiperazine</title>
          <description>Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving.</description>
          <population>The analyses included only those subjects who completed all three types of infusions (saline, meta-Chlorophenylpiperazine, and yohimbine)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.460" spread="1.352"/>
                    <measurement group_id="O2" value="5.416" spread="1.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Craving Rating in Response to Yohimbine Infusion</title>
        <description>Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving.</description>
        <time_frame>180 minutes after the start of the infusion</time_frame>
        <population>The analyses included only those subjects who completed all three types of infusions (saline, meta-Chlorophenylpiperazine, and yohimbine)</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Subjects received 3 tablets of 333mg acamprosate three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received 3 tablets of placebo three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Craving Rating in Response to Yohimbine Infusion</title>
          <description>Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving.</description>
          <population>The analyses included only those subjects who completed all three types of infusions (saline, meta-Chlorophenylpiperazine, and yohimbine)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.613" spread="1.140"/>
                    <measurement group_id="O2" value="3.606" spread="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acamprosate</title>
          <description>Subjects received 3 tablets of 333mg acamprosate three times daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects received 3 tablets of placebo three times daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Racing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomach Ache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Dreaming</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abundance of Energy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aggressiveness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Euphoria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Impaired Concentration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lack of Energy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Shakiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sleeplessness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lack of Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Feeling Down</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mood Swings</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Paranoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Interest in Sex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Painful Erections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coughing Spells</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tightening of Airways</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sensation of Prickling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Markus Heilig</name_or_title>
      <organization>NIAAA, NIH</organization>
      <phone>301.435.9386</phone>
      <email>mheilig@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

